Tier 4 — mechanistic

Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors

Wake Forest University Health Sciences study team
ClinicalTrials.gov trial registry record 2025

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Wake Forest University Health Sciences.
Competing interests
Not reported in the registry record.

Study snapshot

DesignProspective randomized double-blind placebo-controlled crossover pilot trial.
ModelCancer survivors aged 65 years or older with self-reported fatigue.
SampleEstimated enrollment: 60 participants.
InterventionParticipants receive fisetin or placebo on two consecutive days in each of two consecutive weeks, then cross over after a 14-day washout; the current public registry should be consulted for exact dispensing instructions.
DurationTwo 2-week treatment periods separated by a 14-day washout, with follow-up through 12 weeks.
EndpointsFatigue; Safety; Adherence; Exploratory blood biomarkers

What the study showed, in plain terms

This Wake Forest pilot asks whether short-course fisetin can reduce fatigue in older cancer survivors. Its crossover design means each participant receives both fisetin and placebo in different periods.

The trial began in December 2025 and was recruiting at the latest public update. No results are available, so it cannot yet support a claim that fisetin reduces cancer-related fatigue.

Key findings

  • Estimated enrollment is 60 cancer survivors aged 65 years or older.
  • The study uses a randomized double-blind crossover design.
  • The primary clinical question is fatigue, not longevity or systemic senescent-cell clearance.

What this study can and cannot tell us

  • No outcome results are available.
  • Pilot sample and short treatment windows limit conclusions.
  • Cancer-survivor findings may not generalize to otherwise healthy older adults.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology